However, traditional approaches to regulatory intelligence – largely manual and reactive – are no longer sufficient to manage the pace, volume, and complexity of regulatory changes. Enter artificial intelligence (AI).

AI is fundamentally transforming how pharmaceutical companies approach regulatory intelligence. From automated monitoring of global health authority updates to predicting regulatory trends and accelerating submission planning, AI empowers regulatory teams to become more proactive, agile, and informed.

In this blog, we explore the transformative role of AI in advancing pharma regulatory intelligence, the technologies involved, and how companies can leverage it for better compliance and strategic advantage.

Understanding Regulatory Intelligence in Pharma

Regulatory intelligence refers to the systematic collection and analysis of regulatory information – such as guidelines, updates, submission requirements, and approval trends – relevant to product development and commercialization.

Effective RI supports:

• Product classification and pathway determination
• Country-specific submission planning
• Labeling strategy and compliance
• Risk mitigation and regulatory change management
• Competitor benchmarking and regulatory forecasting

But traditional RI methods rely heavily on human analysts sifting through vast amounts of data, leading to delays, missed updates, and inconsistent insights.

The AI Advantage in Regulatory Intelligence

AI brings speed, scale, and structure to the otherwise manual processes involved in regulatory intelligence. Here’s how:

1. Automated Monitoring of Regulatory Sources

AI can scan, extract, and categorize updates from hundreds of global health authority websites, databases, and publications – 24/7. Natural language processing (NLP) engines:

• Identify relevant changes in regulations or guidelines
• Classify updates by geography, product type, or therapeutic area
• Alert regulatory teams based on predefined relevance filters

This replaces manual monitoring and ensures no critical updates are missed.

2. Intelligent Search and Retrieval

Instead of manually combing through large documents, AI tools enable advanced semantic search:

• Ask natural language queries like “What are the latest EMA requirements for pediatric formulations?”
• Get accurate, summarized, and source-linked answers instantly
• Surface historical context, related regulations, and precedents

This improves research productivity and decision accuracy.

3. Predictive Regulatory Analytics

Machine learning models can identify patterns in regulatory approvals, deficiencies, and response timelines across regions and therapeutic areas. This enables:

• Forecasting submission timelines and approval probabilities
• Identifying regulatory bottlenecks before they occur
• Benchmarking performance against competitors

Predictive analytics empowers teams to make data-driven, forward-looking decisions rather than reacting to issues post-factum.

4. Regulatory Change Impact Analysis

AI engines can compare changes across document versions and assess downstream impacts on labeling, clinical protocols, CMC sections, or risk management plans.

This helps:

• Prioritize regulatory actions based on business impact
• Route changes to the appropriate SME or functional group
• Reduce the risk of non-compliance due to outdated content

Technologies Powering AI in Regulatory Intelligence

Several AI technologies work together to streamline and strengthen pharma RI:

By integrating these technologies into RI platforms, pharma companies can gain a deeper, faster, and more contextual understanding of the regulatory landscape.

Key Use Cases of AI-Powered Regulatory Intelligence

1. Global Regulatory Monitoring

Track and alert on relevant regulatory developments across FDA, EMA, PMDA, CDSCO, TGA, and more – automatically and in real time.

2. Submission Planning and Readiness

Understand country-specific requirements for eCTD, dossier format, module expectations, and timelines to accelerate planning.

3. Labeling Compliance

Monitor evolving labeling requirements, detect inconsistencies across markets, and flag necessary updates to maintain compliance.

4. Competitor Intelligence

Analyze competitor approval trends, regulatory strategies, and submission timelines using publicly available databases.

5. Risk Assessment and Scenario Planning

Use AI to model various regulatory pathways and assess risk under different regulatory regimes or product profiles.

Benefits of AI in Regulatory Intelligence

When scaled across the organization, these benefits translate to faster product development cycles, lower regulatory risk, and improved market access.

Overcoming Implementation Challenges

While the benefits of AI in regulatory intelligence are clear, successful adoption requires attention to:

• Data quality: AI models need access to accurate, structured data for meaningful insights.
• Integration: AI solutions should integrate with existing regulatory and quality systems (RIM, QMS, DMS).
• Human oversight: Regulatory experts should validate AI-generated insights and provide context-specific judgment.
• Change management: Training, communication, and executive buy-in are key to adoption across global teams.

Partnering with an experienced provider like DDi helps organizations navigate these challenges with pre-built frameworks, domain-trained AI models, and pharma-specific implementation expertise.

The Future of Regulatory Intelligence is AI-Driven

As regulatory agencies themselves begin embracing AI (e.g., the FDA’s Project ProACT), pharma companies must evolve to stay ahead. The future of regulatory intelligence will be:

• Real-time instead of retrospective
• Predictive instead of reactive
• Connected across regions and functions
• Self-learning through feedback loops and automation

Forward-thinking regulatory affairs teams that embrace AI today will not only be more compliant – but also more competitive and innovation-ready.

Conclusion: A Smarter Way to Navigate Regulatory Complexity

The pharmaceutical regulatory landscape is only becoming more complex and dynamic. Traditional methods of managing regulatory intelligence are no longer sufficient for organizations that aim to move fast, scale globally, and reduce compliance risk.

AI offers a new paradigm – one that transforms static information into dynamic insights, streamlines regulatory operations, and equips teams with the tools they need to anticipate and act.

Whether you’re tracking global health authority updates, optimizing submission strategies, or staying ahead of evolving labeling requirements, AI-powered regulatory intelligence is the smart way forward.

Ready to Upgrade Your Regulatory Intelligence with AI?

DDi helps pharma and biotech companies gain a competitive edge through AI-driven regulatory intelligence. From automated global monitoring to predictive insights and workflow integration, our solutions are built for compliance, speed, and scale.

Explore how DDi can transform your regulatory operations.

Enter Artificial Intelligence (AI). When seamlessly integrated with modern RIM platforms, AI has the potential to revolutionize how regulatory data is handled, analyzed, and utilized. This article explores how AI-enabled RIM is becoming a game-changer for leading pharma companies, dramatically improving operational efficiency, team productivity, and global regulatory compliance.

The Strategic Importance of RIM in Pharma

RIM is more than just a repository – it is the regulatory nerve center of a pharmaceutical organization. For global pharma giants, RIM must handle:

• Complex product portfolios
• Multi-region submissions
• Ever-changing global regulations
• Vast amounts of structured and unstructured data

Without a robust, intelligent RIM system, regulatory teams struggle with data silos, duplicate efforts, missed deadlines, and compliance risks. As such, RIM has evolved from a nice-to-have system into a critical component of enterprise-wide digital transformation strategies.

Why AI is a Natural Fit for RIM Systems

AI technologies like machine learning (ML), natural language processing (NLP), and robotic process automation (RPA) are tailor-made for regulatory affairs. Here’s why top pharma companies are leading the charge in adopting AI-integrated RIM solutions:

1. Intelligent Data Management

AI automates the extraction, classification, and validation of data from documents like clinical study reports, labeling records, and regulatory correspondence.

2. Predictive Submission Planning

Machine learning models assess historical data to forecast regulatory timelines, helping teams optimize planning and resource allocation.

3. Global Regulatory Intelligence

NLP tools scan and interpret global regulatory updates in real-time, flagging changes that may affect current filings or future strategies.

4. Automation of Low-Value Tasks

AI bots handle mundane tasks – like status updates, document tagging, or compiling submission packages – freeing up RA teams for higher-value activities.

Enhancing Efficiency Across Global Regulatory Operations

Efficiency is no longer optional in a market driven by speed. For pharma companies, integrating AI into RIM translates into substantial efficiency gains across all regulatory operations.

• Streamlined Submissions: Automated data entry, template population, and validation checks reduce submission preparation time by up to 40%.
• Centralized Access: AI-enabled platforms offer a 360-degree view of regulatory activities, simplifying portfolio management across regions.
• Real-Time Dashboards: Advanced analytics and dashboards provide actionable insights into KPIs, resource utilization, and submission statuses.

These capabilities not only reduce time-to-market but also strengthen regulatory strategy across complex geographies.

Maximizing Team Productivity with Intelligent Tools

Regulatory professionals are among the most overburdened teams in pharma. AI empowers them by shifting the focus from manual work to strategic decision-making.

• Smart Workflow Management: AI algorithms route tasks, assign priorities, and optimize workloads automatically.
• Collaboration Made Easy: Integrated platforms allow cross-functional teams (RA, clinical, CMC, labeling) to work together seamlessly with real-time document sharing and feedback loops.
• Onboarding & Knowledge Retention: AI systems act as a knowledge base, preserving institutional memory and enabling faster onboarding of new staff.

This shift improves team morale, reduces burnout, and creates a culture of strategic thinking and agility.

AI and RIM: A Powerful Duo for Regulatory Compliance

Compliance is the bedrock of pharma success, and for global leaders, it means navigating a constantly shifting regulatory maze. Here’s how AI strengthens compliance:

• Proactive Compliance Monitoring: AI tracks global regulatory changes, automatically updates records, and alerts teams to act before non-compliance risks escalate.
• Gap and Impact Analysis: When a regulatory update is issued, AI tools assess which products or dossiers are affected and recommend necessary actions.
• Audit Readiness: Every action taken in an AI-powered RIM system is logged, traceable, and reportable – making audit prep faster, easier, and stress-free.

These proactive capabilities help top pharma firms avoid fines, delays, and reputational risks associated with non-compliance.

Use Cases: AI-Driven RIM in Action at Pharma

Several leading pharmaceutical companies have already reaped significant benefits from AI-enabled RIM platforms. Let’s explore a few real-world examples that highlight its transformative power:

Case Study 1: Accelerated Submission Turnaround

A global top 10 pharma leveraged AI to automate the extraction and structuring of data from clinical study reports. This cut submission preparation time by nearly 50%, enabling faster approvals in highly competitive markets.

Case Study 2: Proactive Compliance in Emerging Markets

A multinational pharma operating in over 80 countries used AI-driven regulatory intelligence tools to monitor and analyze updates from hundreds of health authorities. This allowed the company to implement changes within days instead of weeks, ensuring seamless compliance across borders.

Case Study 3: Optimized Workflows and Resource Allocation

A top 20 firm integrated AI into its RIM system to manage over 10,000 regulatory tasks annually. AI helped prioritize workloads, reducing project delays by 30% and enhancing overall team productivity.

These cases underscore that AI isn’t just theoretical – it’s delivering measurable improvements right now in regulatory operations at scale.

Overcoming Challenges in AI-RIM Adoption

Despite the clear benefits, implementing AI in regulatory affairs isn’t without challenges – especially for large pharma enterprises:

• Data Quality and Standardization: AI models require clean, structured data. Legacy systems and inconsistent formats can hinder performance.
• Change Management: Teams accustomed to traditional methods may resist the adoption of AI tools. Strong leadership and tailored training are critical.
• Integration Complexity: Integrating AI with existing RIM and enterprise systems (e.g., ERP, LIMS, QMS) demands careful planning and investment.
• Regulatory Trust and Validation: Health authorities must trust that AI-generated data and decisions are accurate and validated. Transparency and compliance with validation requirements are essential.

To overcome these challenges, top pharma companies are forming cross-functional governance teams, investing in pilot programs, and partnering with experienced technology providers.

Key Features to Look for in AI-Enabled RIM Solutions

Choosing the right platform is pivotal for success. Regulatory leaders in pharma should look for RIM systems with:

• AI-Powered Analytics for submission planning, compliance tracking, and risk prediction
• Natural Language Processing for global regulatory intelligence and document parsing
• Robust Integration Capabilities with other enterprise systems
• Global Scalability to support regional variations in regulatory requirements
• Configurable Dashboards and Reporting Tools to enable real-time decision-making

Additionally, cloud-native architecture, multilingual support, and robust cybersecurity features are non-negotiables for global enterprises.

The Future: AI-Powered Regulatory Strategy

Looking ahead, AI will not only optimize regulatory operations but shape proactive regulatory strategies. Here’s what the future could hold for top 50 pharma companies:

• Digital Twins for Regulatory Submissions: Simulate and test different regulatory pathways before actual submission.
• Conversational AI for Regulatory Queries: Real-time, voice-activated assistants to support on-the-fly regulatory decision-making.
• AI-Driven Labeling: Automate global labeling updates with NLP, reducing delays and ensuring consistency across SKUs.
• Regulatory Forecasting Models: Predict regulatory challenges before they occur and adjust strategies accordingly.

Pharma companies that embrace AI and digital transformation in RIM now will gain a lasting competitive edge as regulatory expectations and market demands continue to evolve.

Conclusion

AI-enabled RIM systems like Visu are not just enhancing regulatory operations – they’re redefining them. For pharmaceutical companies, the integration of Artificial Intelligence into Regulatory Information Management represents a strategic advantage: faster submissions, stronger compliance, smarter decisions, and scalable operations.

Why a Scalable RIM Strategy is Critical in Pharma and Biotech

The pharmaceutical and biotech sectors are governed by a maze of stringent regulations across global markets. From the FDA to the EMA, from PMDA in Japan to ANVISA in Brazil – every region has its own requirements, documentation standards, and approval processes. As your company expands into new markets or grows its product portfolio, your regulatory workload multiplies. A scalable RIM system makes this growth manageable.

Imagine trying to keep track of submission timelines, regulatory status updates, health authority communications, and product lifecycle changes manually – inefficient, error-prone, and risky. A scalable strategy not only supports growing operations but also ensures data integrity, improves collaboration, and reduces compliance risk.

What Is Regulatory Information Management (RIM)?

At its core, RIM refers to the centralized management of all regulatory activities and information. It includes:

• Submission tracking and planning
• Health authority correspondence
• Product registrations and renewals
• Labeling and artwork approvals
• Document management and archiving

RIM is the backbone of any regulatory operations team. With the right tools and strategy, it shifts from a reactive, compliance-centric function to a proactive, strategic driver of efficiency.

Key Elements of a Scalable RIM Strategy

A scalable RIM strategy isn’t just about technology – it’s about aligning people, processes, and tools. Let’s break it down.

1. Centralized Data Repository

A single source of truth is vital. All product, regulatory, and submission data should live in one unified system that’s accessible across departments. This reduces duplication, minimizes inconsistencies, and streamlines audits and inspections.

2. Automation and Workflow Integration

Scalability thrives on automation. From approval workflows to submission tracking, automation reduces manual tasks, accelerates turnaround times, and improves consistency. Think of it as a digital assembly line for your regulatory activities.

3. Real-Time Collaboration and Communication

Whether your teams are across countries or departments, real-time collaboration tools integrated into your RIM platform can drastically improve coordination. Everyone stays aligned, reducing miscommunication and delays.

4. Regulatory Intelligence Integration

Your RIM system should be able to ingest and respond to real-time changes in global regulations. Staying compliant isn’t just about submitting on time – it’s about adapting to new requirements instantly.

5. Compliance and Audit Readiness

A good RIM strategy ensures you’re always audit-ready. That means version-controlled documentation, traceable records, and comprehensive audit trails – all available at your fingertips.

Steps to Build a Scalable RIM Strategy

Creating a scalable RIM strategy is a journey. Here’s a step-by-step roadmap to get you there.

Step 1: Evaluate Current State

Start with a full audit of your current regulatory processes. Where are the inefficiencies? Are there silos between teams? What tools are you using? This gives you a baseline for improvement.

Step 2: Define Clear Objectives

Do you want to reduce submission times? Improve compliance visibility? Support expansion into new markets? Set measurable goals to guide your strategy.

Step 3: Choose the Right Technology

Not all RIM solutions are created equal. Look for systems designed for scalability, flexibility, and integration. They should support multiple product lines, geographies, and regulatory requirements.

Step 4: Map Out Scalable Workflows

Design standardized workflows that can be applied across different projects or regions. Ensure they are flexible enough to adapt to changing requirements.

Step 5: Train and Onboard Your Teams

People are the backbone of your strategy. Provide comprehensive training to ensure your teams can use the RIM system effectively. Encourage feedback to continuously improve processes.

Step 6: Monitor and Optimize

Regularly review your RIM performance using KPIs. Are you meeting submission deadlines? Are processes smooth? Use this data to refine and evolve your strategy.

Choosing a Scalable RIM Platform: What to Look For

The market is flooded with RIM platforms, but not all are built for growth. Here’s what to prioritize:

• Modular design: Grow the system with your business needs
• Cloud-based: Access data anytime, anywhere
• Integration-friendly: Connect with existing systems like ERP or document management tools
• User-friendly interface: Simplifies training and adoption
• Strong support and updates: Choose a vendor that evolves with the regulatory environment

DDi’s Visu platform stands out for its integrated approach to regulatory information and process management for pharma and biotech.

Benefits of a Scalable RIM Strategy

Still wondering if this investment is worth it? Here’s what you gain:

• Faster Submissions: Speed up approval timelines with better coordination
• Global Visibility: Track regulatory status across all markets in one dashboard
• Improved Compliance: Reduce the risk of non-compliance with timely reminders and alerts
• Audit Readiness: Always be prepared with complete traceability and document control
• Operational Efficiency: Reduce workload through automation and process optimization

Real-World Impact: Case Study Snapshot

Let’s say a mid-sized biotech company expands into APAC and Latin America. Each country has different requirements, document formats, and submission timelines. Without a scalable RIM system, managing these differences could delay approvals by months.

After adopting Visu, a cloud-based RIM solution by DDi, they standardized document templates, created region-specific workflows, and set up real-time tracking dashboards. The result? A 40% faster submission rate and a 30% drop in manual errors.

Common Mistakes to Avoid When Scaling RIM

• Overcustomization: Flexibility is good, but too many tweaks can make systems unstable.
• Neglecting Training: A powerful tool is useless if your team can’t use it properly.
• Ignoring Integration: A RIM system that doesn’t integrate with other tools creates more work, not less.
• Focusing Only on Compliance: Scalability is about growth, not just staying in line.

Future-Proofing Your RIM Strategy

To ensure your RIM strategy remains scalable:

• Stay updated on regulatory changes
• Regularly revisit and refine workflows
• Invest in continuous learning and development
• Use AI/ML for predictive analytics and submission planning
• Adopt feedback loops with regulatory teams for constant improvement

Conclusion

A scalable Regulatory Information Management strategy isn’t just a nice-to-have – it’s mission-critical for any growing pharma or biotech organization. From improving submission timelines to ensuring global compliance, the right RIM approach transforms your regulatory operations into a strategic advantage. Whether you’re just starting out or scaling up, now is the time to future-proof your RIM framework.

Impact assessments provide a structured approach to evaluating potential risks, regulatory changes, and other external factors that could affect a pharmaceutical product. This blog will explore why impact assessment is critical in the pharmaceutical product lifecycle and how it helps companies maintain compliance, reduce risks, and bring high-quality products to market.

What is Impact Assessment in Pharmaceutical Product Lifecycle Management?

An impact assessment is a systematic process of evaluating the effects of various factors on a product or process. In the context of pharmaceutical product lifecycle management, impact assessments help identify potential risks and changes that could affect a drug’s safety, efficacy, regulatory compliance, and market success. These assessments are conducted at different stages of the product lifecycle, from initial research and development to post-market surveillance.

Impact assessments in PLM typically consider factors such as:

• Regulatory changes that may require adjustments to product development or labeling.
• Market dynamics that could impact pricing, demand, or competition.
• Supply chain disruptions that could delay product availability or increase costs.
• Technological advancements that may affect drug formulation, packaging, or delivery methods.

By proactively assessing these factors, pharmaceutical companies can make informed decisions and adjust their strategies to mitigate risks and ensure that their products remain compliant and competitive.

The Stages of Pharmaceutical Product Lifecycle and the Role of Impact Assessment

The pharmaceutical product lifecycle consists of several stages, each of which presents unique challenges and opportunities. Impact assessments play a crucial role in navigating these stages successfully.

1. Research and Development (R&D)

The first stage of the pharmaceutical product lifecycle is research and development. During this phase, companies are focused on discovering new drugs, conducting preclinical studies, and developing formulations that will be safe and effective for human use.

Why Impact Assessment is Critical:

• Identifying Risks Early: Impact assessments during R&D help identify potential risks associated with drug development, such as safety concerns, ethical considerations, or regulatory hurdles. By addressing these risks early on, companies can avoid costly delays and improve the likelihood of success in later stages.
• Regulatory Compliance: As global regulatory bodies have strict guidelines for drug development, conducting an impact assessment ensures that the product development strategy aligns with regulatory requirements from the beginning, minimizing the risk of non-compliance.

2. Clinical Trials

After the R&D phase, the drug enters clinical trials, where it is tested on human subjects to evaluate its safety, efficacy, and optimal dosage. Clinical trials are divided into three phases, each with its own objectives and regulatory requirements.

Why Impact Assessment is Critical:

• Regulatory Changes: Impact assessments help companies stay up to date with any changes in clinical trial regulations, such as new guidelines from the FDA, EMA, or other regulatory bodies. Ensuring compliance with these guidelines is crucial for the successful progression of the drug through each trial phase.
• Ethical Considerations: Clinical trials must meet high ethical standards to protect participants. An impact assessment can identify potential ethical issues, such as trial design or participant consent, and ensure they are addressed before trials begin.
• Resource Allocation: Impact assessments help companies assess the potential costs and resources required for clinical trials, ensuring that they have the necessary budget and personnel to conduct trials effectively.

3. Regulatory Submission and Approval

Once a drug has successfully passed clinical trials, it must be submitted for regulatory approval. This involves preparing a comprehensive dossier that includes clinical trial data, manufacturing information, and other relevant documentation.

Why Impact Assessment is Critical:

• Meeting Submission Requirements: Impact assessments ensure that all necessary documents and data are included in regulatory submissions. Missing or incomplete information can lead to delays in approval, so it’s critical that companies conduct thorough assessments to avoid such issues.
• Evaluating Market Potential: Before submitting a drug for approval, companies need to assess the potential market impact. This includes analyzing the competitive landscape, pricing strategies, and potential demand for the drug. An impact assessment helps identify opportunities and risks, allowing companies to adjust their market strategy as needed.
• Global Compliance: Impact assessments are especially important for companies seeking approval in multiple regions, as they must comply with different regulatory requirements in each market. Conducting an impact assessment ensures that the product meets the standards of each regulatory body.

4. Product Launch

After receiving regulatory approval, the drug is ready for market launch. This phase involves manufacturing, marketing, and distribution efforts to bring the product to consumers.

Why Impact Assessment is Critical:

• Supply Chain Readiness: Impact assessments can help identify potential bottlenecks or disruptions in the supply chain that could delay the product launch. This is particularly important for ensuring that the product is available in sufficient quantities to meet market demand.
• Market Strategy Adjustment: Impact assessments can reveal changes in market conditions, such as new competitors, pricing shifts, or changes in consumer behavior. By evaluating these factors, companies can adjust their marketing and distribution strategies to optimize the product launch.
• Compliance Monitoring: Even after the product is launched, regulatory requirements must continue to be met. Impact assessments help monitor compliance with labeling, marketing claims, and post-market surveillance requirements, reducing the risk of regulatory action.

5. Post-Market Surveillance

After the product is on the market, it is subject to ongoing monitoring to ensure that it remains safe and effective. This includes tracking adverse events, monitoring product performance, and responding to regulatory updates.

Why Impact Assessment is Critical:

• Adverse Event Monitoring: Impact assessments help companies track and respond to adverse events reported by healthcare providers or patients. If any safety concerns arise, an impact assessment can guide decision-making regarding product recalls, labeling changes, or additional warnings.
• Regulatory Updates: As regulatory requirements evolve; impact assessments help companies stay compliant by identifying new regulations that may affect their product. For example, new labeling requirements or changes in post-market reporting standards can be addressed through a well-conducted impact assessment.
• Product Lifecycle Management: Impact assessments are essential for managing the entire product lifecycle, including decisions about product updates, discontinuation, or the introduction of new formulations. By evaluating market performance and regulatory factors, companies can make informed decisions about the future of their products.

The Benefits of Conducting Regular Impact Assessments in PLM

Conducting regular impact assessments throughout the product lifecycle offers numerous benefits to pharmaceutical companies, including:

• Risk Mitigation: By identifying potential risks early, companies can take proactive steps to address them, reducing the likelihood of costly mistakes or delays.
• Improved Decision-Making: Impact assessments provide valuable insights into market conditions, regulatory requirements, and other factors that influence product success. This enables companies to make informed decisions about product development, launch, and lifecycle management.
• Regulatory Compliance: Regular impact assessments help ensure that companies remain compliant with regulatory requirements, reducing the risk of fines, product recalls, or delays in approval.
• Enhanced Market Competitiveness: By evaluating market dynamics and adjusting strategies accordingly, impact assessments help companies maintain a competitive edge and maximize the commercial potential of their products.

Conclusion

Impact assessment is a critical component of pharmaceutical product lifecycle management. From R&D to post-market surveillance, conducting thorough impact assessments at each stage helps companies mitigate risks, ensure regulatory compliance, and optimize product success. As the pharmaceutical industry continues to evolve, the importance of impact assessments will only grow, making them an essential tool for any company looking to succeed